NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: MANGALAM · data 2026-11-01
Mangalam Drugs & Organics Ltd.
In plain words
Price: 57.4% below its 52-week high of ₹67.19.
Delivery: 73.3% of traded shares were kept for delivery over the last 10 sessions, against 70.1% over the last 60.
Latest results: a net loss of ₹8 cr for the quarter ended Jun 2026.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹232 cr |
| Net profit (last 12 months) | ₹-38 cr |
| Sales growth, 3 years (yearly) | -14.7% |
| Profit growth, 3 years (yearly) | — |
At a glance
Promoters 35.6% (-14.6 pts in a year), pledged 0.0%, institutions 0.1%.
ROE -35.2%, ROCE -22.8%, operating margin -11.5%: how much profit it earns on the money it uses.
Debt/equity 1.08, Profit growth — and sales growth -14.7% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Low return on equity (-35.2%).
- Thin operating margin (-11.5%).
- Promoters cut their holding by 14.6 points in a year.
- Reported a loss in the latest quarter.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
MANGALAM Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹57.12 crore, down 0.4% YoY and down 15.1% QoQ.
Net loss was ₹7.64 crore, a smaller loss than a year ago and a smaller loss than last quarter.
Operating margin was 1.6% (7.8% a year ago).
EPS was -₹4.83, less negative than a year ago and less negative than last quarter.
MANGALAM के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹57.12 करोड़; पिछले साल की तुलना में 0.4% की गिरावट, पिछली तिमाही की तुलना में 15.1% की गिरावट।
शुद्ध घाटा: ₹7.64 करोड़; एक साल पहले से घाटा कम हुआ, पिछली तिमाही से घाटा कम हुआ।
ऑपरेटिंग मार्जिन: 1.6% (एक साल पहले 7.8%)।
EPS: -₹4.83; एक साल पहले से कम ऋणात्मक, पिछली तिमाही से कम ऋणात्मक।
MANGALAMના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹57.12 કરોડ; ગયા વર્ષની સરખામણીએ 0.4% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 15.1% ઘટાડો.
ચોખ્ખી ખોટ: ₹7.64 કરોડ; એક વર્ષ પહેલાંની સરખામણીએ ખોટ ઘટી, ગયા ક્વાર્ટરની સરખામણીએ ખોટ ઘટી.
ઓપરેટિંગ માર્જિન: 1.6% (એક વર્ષ પહેલાં 7.8%).
EPS: -₹4.83; એક વર્ષ પહેલાંના કરતાં ઓછી નકારાત્મક, ગયા ક્વાર્ટરના કરતાં ઓછી નકારાત્મક.
Written from the filed numbers. Not a recommendation.
Smart-money activity
5/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Delivery 64.5% over the last 20 sessions vs 67.2% in the 40 before (0.96x); shares delivered per day 0.48x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results
- 12 Aug 26Results Q1 FY27 results: loss narrowed vs a year ago +3.2% next session
- 14 May 26Results Q4 FY26 results: turned to loss vs a year ago -2.2% next session
- 15 Jan 26Results Q3 FY26 results: turned to loss vs a year ago +5.0% next session
- 8 Dec 25Results Q2 FY26 results: turned to loss vs a year ago -3.0% next session
- 20 Nov 25Results Results board meeting -14.7% next session
- 13 Nov 25Results Results board meeting -0.4% next session
- 19 Aug 25Results Q1 FY26 results: turned to loss vs a year ago -0.8% next session
- 7 Aug 25Results Results board meeting -9.4% next session
- 19 May 25Results Q4 FY25 results: profit −98.3% YoY -3.5% next session
- 14 Feb 25Results Q3 FY25 results: profit +158.0% YoY -4.2% next session
- 15 Nov 24Results Q2 FY25 results: net profit ₹2.7 cr +1.0% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹57 cr | ₹-8 cr | — | 1.6% | -4.83 |
| Mar 2026 | ₹67 cr | ₹-13 cr | -22466.7% | -8.4% | -8.48 |
| Dec 2025 | ₹58 cr | ₹-10 cr | -862.8% | -2.4% | -6.21 |
| Sept 2025 | ₹50 cr | ₹-7 cr | -373.2% | -5.7% | -4.64 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 35.65% | 35.65% | 35.65% | 35.64% |
| Foreign institutions (FII) | 0.11% | 0.11% | 0.32% | 0.13% |
| Domestic institutions (DII) | 0.00% | 0.00% | 0.00% | 0.00% |
| Mutual funds | — | — | — | 0.00% |
| Retail investors | 50.02% | 50.19% | 50.48% | 42.02% |
| Number of shareholders | 23,991 | 24,465 | 25,140 | 21,227 |
Common questions
What was Mangalam Drugs & Organics Ltd.'s latest quarterly profit?
Mangalam Drugs & Organics Ltd. reported a net loss of ₹8 cr for the quarter ended Jun 2026, on revenue of ₹57 cr.
How much do promoters hold in Mangalam Drugs & Organics Ltd.?
Promoters held 35.65% of Mangalam Drugs & Organics Ltd. at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Mangalam Drugs & Organics Ltd. debt-free?
Its latest reported debt-to-equity ratio is 1.08, meaning borrowings are larger than shareholders' equity.
What is the 52-week high and low of Mangalam Drugs & Organics Ltd.?
The 52-week high is ₹67.19 and the 52-week low is ₹22.8.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Mangalam Drugs & Organics Ltd. | ₹28.61 | ₹46 cr | — | — | -35.2% | -22.8% | 1.08 | -58.2% |
| Onyx Biotec Ltd. | ₹36 | ₹65 cr | — | — | -0.4% | 0.5% | 0.27 | -12.4% |
| Zenith Drugs Ltd. | ₹37 | ₹63 cr | 16.1 | 0.9 | 5.5% | 9.3% | 0.75 | -40.5% |
| Vivimed Labs Limited | ₹5.53 | ₹51 cr | — | — | — | -43.6% | — | +5.3% |
| Biofil Chemicals & Pharmaceuticals Ltd. | ₹28.68 | ₹47 cr | 96.4 | — | 13.8% | 1.8% | 0.14 | -27.5% |
| Medicamen Organics Ltd. | ₹26.5 | ₹39 cr | — | — | -13.7% | -15% | 0.5 | -24.6% |
Compare MANGALAM with ONYX in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open MANGALAM in NSE Scanner →